AS
Astrana Health, Inc.
ASTH · NASDAQ
$34.30 -8.07% (-$3.01)
1M -12.94%
Market Cap $1.70B
P/E Ratio 41.94x
Div. Yield -
ROE 5.09%
Bulios Fair Price
$42.17
22.9% upside
Current Price
$34.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ASTH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
64 /100
Fair P/S 0.44x
P/E 41.94x
P/B 2.05x
Growth
68 /100
Growing FCF growth 20.86%
EPS growth 22.55%
Book val. growth 12.83%
Profitability
16 /100
Weak Op. margin 2.61%
Gross margin 9.22%
FCF margin 4.12%
Quality
32 /100
Poor ROA 1.78%
ROIC 4.10%
Asset turnover 1.68x
Debt
39 /100
Moderate Int. coverage 1.89x
Debt/Equity 1.18x
Net debt/EBITDA 3.31x
Stability
70 /100
Stable EPS volatility 41.40%
Beta 0.91x
Profitable years 5
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ASTH
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Brandon K. Sim
Employees
3,000
Headquarters
Alhambra
Upcoming events
05 NOV
Earnings
Upcoming earnings report